Recent studies have reported that SSE can modulate asthma reactions and pulmonary damage via inhibition of the expression of cyclooxygenase 2 (COX-2), of inflammatory cytokines and of the activation of NF-κB (Cho et al., 2008; Kim et al., 2013). The gene discussed is NFKB1; the disease is asthma.